Kuros Biosciences AG (KURN):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10136)
◆英語タイトル:Kuros Biosciences AG (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10136
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG (KURN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kuros Biosciences AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Kuros Biosurgery Raises Additional USD5 Million Financing 12
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 13
Merger 14
Cytos Biotech Merges with Kuros Biosurgery 14
Licensing Agreements 15
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Equity Offering 18
Kuros Biosciences to Raise up to USD30.2 Million in Private Placement of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Kuros Biosciences Raises Funds through Public Offering of Shares 20
Cytos Biotechnology Completes Rights Offering Of Shares For US$26.7 Million 21
Cytos Biotechnology Completes Private Placement Of Shares For US$26 Million 22
Cytos Biotechnology Completes Rights Offering Of Shares For US$3.5 Million 24
Debt Offering 26
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For US$14.5 Million 26
Kuros Biosciences AG – Key Competitors 28
Kuros Biosciences AG – Key Employees 29
Kuros Biosciences AG – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 05, 2018: Kuros Biosciences announces results for first half 2018 31
Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results 32
Sep 26, 2017: Kuros Biosciences Reports Financial Results for First Half-Year of 2017 33
Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016 34
Corporate Communications 36
Aug 23, 2018: Kuros Biosciences names Pascal Longlade as chief medical officer 36
May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM 37
Dec 14, 2017: Kuros Biosciences Announces Management Succession 38
Nov 28, 2017: Kuros Biosciences’ Chief Medical Officer to Retire 39
Nov 16, 2017: Kuros announces management changes 40
Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members 41
Apr 13, 2017: Kuros announces CEO succession 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kuros Biosciences AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kuros Biosciences AG, Deals By Therapy Area, 2012 to YTD 2018 9
Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kuros Biosurgery Raises Additional USD5 Million Financing 12
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 13
Cytos Biotech Merges with Kuros Biosurgery 14
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Kuros Biosciences to Raise up to USD30.2 Million in Private Placement of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Kuros Biosciences Raises Funds through Public Offering of Shares 20
Cytos Biotechnology Completes Rights Offering Of Shares For US$26.7 Million 21
Cytos Biotechnology Completes Private Placement Of Shares For US$26 Million 22
Cytos Biotechnology Completes Rights Offering Of Shares For US$3.5 Million 24
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For US$14.5 Million 26
Kuros Biosciences AG, Key Competitors 28
Kuros Biosciences AG, Key Employees 29
Kuros Biosciences AG, Subsidiaries 30

List of Figures
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kuros Biosciences AG, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Kuros Biosciences AG (KURN):製薬・医療:M&Aディール及び事業提携情報(Kuros Biosciences AG (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆